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Abstract
Introduction
Left atrial appendage closure (LAAC) with LARIAT offers an alternative to oral anticoagula-
tion (OAC) for patients with atrial fibrillation. The aim of this study was to present long-term
clinical outcomes of LAAC in these patients (AF).
Material and methods
A prospective, single-center study was performed in 139 patients undergoing LAAC with
Lariat. Thromboembolic events, severe bleeding and mortality rate were recorded. The
reduction in risk of thromboembolism and bleeding after LAAC was calculated.
Results
The mean CHADS2-score was 1.8 ± 1.0, mean CHA2DS2-VASc score was 2.9 ± 1.6 and
HAS-BLED score was 3.1 ± 1.1. After 428.4 patient-years of follow-up (mean 4.2±1.0
years), the thromboembolism rate was 0.6% with a calculated thromboembolism risk reduc-
tion of 81%. The severe bleeding rate was 0.8%; calculated bleeding risk reduction was
78%. The overall mortality rate was 1.6%.
Conclusions
Long-term outcomes show that LAAC with Lariat is a safe and effective treatment for stroke
prevention and bleeding risk reduction in AF patients with a high level of underlying risk.
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Introduction
Left atrial appendage closure (LAAC) for stroke prevention in patients with atrial fibrillation
(AF) is one of the fastest developing branches of interventional cardiology with the number of
procedures rising annually. Currently, LAAC procedures are a recommended alternative for
AF patients in whom oral anticoagulation (OAC) therapy is ineffective or contraindicated
[1,2].
Exclusion of the left atrial appendage (LAA) may be performed using endocardial (Watch-
man, Amplatzer) or epicardial (Lariat) devices [3]. In contrast to endocardial devices, epicar-
dial devices is an non-implant solution with does not inhibit a post LAA closure ablation
procedure.
Long-term outcomes of AF patients treated with endocardial devices have demonstrated
the safety and efficacy of this approach [4,5]. However, long-term outcome studies for epicar-
dial devices are currently lacking. [3,6].
In this study we evaluated the long-term outcomes of patients with AF treated with the Lar-
iat device in a single center.
Materials and methods
All patients were fully informed about the procedure and gave written informed consent. The
protocol was conducted with the approval of the Polish Ministry of Health and the ethics com-
mittee at John Paul II Hospital, Krakow, Poland.
A prospective, single-center study was performed in 139 patients, who were referred
between December 2009 and December 2012 for LAAC with the LARIAT device. Left atrial
appendage occlusion with the first generation of LARIAT device (SentreHEART Inc, Red-
wood, CA) has been described in detail in previous studies [7–10]. Briefly, the procedure is
performed with three main components: a compliant occlusion balloon, two magnet-tipped
guide wires, and a 12-Fr suture delivery device. Following percutaneous pericardial approach,
trans-septal puncture is performed. The first endocardial magnet-tipped guidewire is placed
near the apex of the LAA. Using percutaneous femoral access, the second endocardial magnet-
tipped guidewire is placed at the tip of the LAA to establish a stable connection between the
wires. The LARIAT snare device is then advanced over the epicardial guidewire to occlude the
LAA. After TEE and fluoroscopic confirmation of LAA closure a pre-tied suture is deployed
and tightened to ligate the LAA. During procedure no periprocedural colchicine for pericardi-
tis prophylaxis were used [3,7,8].
Post-procedure anticoagulation
Antiplatelet therapy with aspirin was recommended for all patients. However, final therapy
varied due to patient comorbidities, contraindications, and physician preference.
Thromboembolism and bleeding reduction calculation
Adverse events reported during follow-up visit, based on the Munich consensus document
[11], included mortality (cardiovascular, non-cardiovascular, procedural mortality, immediate
procedural mortality), thromboembolic events (stroke, TIA, systemic embolism) and bleeding
(life threating or disabling, major bleeding, minor bleeding).
As in our previous study[12], individual patients’ annual risk was recorded, and the average
annual risk for the entire study population was calculated. The total number of thromboem-
bolic events during overall follow-up periods were divided by the total patient years of follow-
up and were multiplied by 100 to get the actual annual rate of thromboembolic events.
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Thromboembolism reduction was calculated as follows: (estimated %—actual % event rate)/
estimated % event rate) [12,13]. Procedure efficacy to prevent thromboembolic events (stroke,
TIA, systemic embolism, thrombus in the heart chamber) was calculated by comparing the
actual event rate with the event rate predicted by the CHA2DS2-VASc scores [1,14,15]. Annual
risk was recorded both for individual patients and the study population overall [12,13].
Bleeding reduction was assessed in a similar manner [12,13], comparing actual events with
the number predicted by the HAS-BLED score [16].
Statistical analysis
Continuous variables were analyzed for normal distribution using the Shapiro-Wilk test. Data
are expressed as mean ± standard deviation or median (interquartile range; Q1-25th percentile
and Q3-75th percentile), unless otherwise stated. If a non-parametric test was used, the
obtained data were additionally presented as mean ± standard deviation for better comparison
with other studies. To assess the differences between two continuous variables, a Student’s t-
test, or Mann-Whitney U-test were used as appropriate. Categorical variables were expressed
as counts and percentages. Baseline characteristics between groups were compared using the t
test for continuous variables and the chi-square test for categorical variables. Kaplan-Meier
analysis was performed to estimate survival over time. Statistical analysis was performed with
STATISTICA 10.0 (StatSoft, Tulsa, OK, USA). A two-sided p-value <0.05 was considered sta-
tistically significant.
Results
Patients baseline characteristics are summarized in Table 1. The mean CHADS2-score was
1.8 ± 1.0, mean CHA2DS2-VASc score 2.9 ± 1.6 and HAS-BLED score 3.1 ± 1.1. Prior to the
procedure 85.6% patients were taking VKA, 12.2% an antiplatelet agent and 2.2% received no
anticoagulation.
Procedure related adverse events was noted in 3 (2.1%) cases. Two patients had a right ven-
tricle puncture requiring drainage and observation resolved without cardiac surgery interven-
tion. One patient developed a pericardial effusion during transseptal puncture due to
superficial epigastric artery laceration requiring cauterization.
Total follow-up was 428.4 patient-years. During the study period, the average annual
thromboembolic event rate was 0.6%: there was one episode of stroke and 2 episodes of throm-
bus in the LA (which resolved with unfractionated heparin with no further complications).
The annual rate of severe bleeding complications was 0.8%: three episodes of hemorrhagic
stroke and one episode of gastrointestinal bleeding. Overall annual mortality rate was 1.63%.
Detailed data are present in Table 2.
Estimated thromboembolic risk reduction and estimated bleeding risk reduction are pre-
sented in Fig 1.
Discussion
This study demonstrates that the epidocardial approach for LAAC is safe and effective over
long-term observations. We demonstrated significant reductions in the expected rate of stroke,
thromboembolism and bleeding complications following LAAC for patients with AF.
Current ESC [1] and ACC/AHA/HRS [17] guidelines recommend OAC for stroke and
thromboembolic prevention (class IA recommendation) in patients with AF and prior stroke
or CHA2DS2-VASc scores� 2. However, there is a large group of patients in whom OAC ther-
apy is contraindicated or ineffective [1,17] or in whom OAC present fatal complications
observed that are observed also in new oral anticoagulants[18]. In recent years LAAC has
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become an increasingly popular alternative [19–21]. ESC guidelines now include LAAC as a
Class 2 B recommendation for patients with AF with a contraindication to OAC or a clinical
history of severe bleeding [1]. Some cardiology associations are also starting to expand LAAC
indications to include patients in whom OAC is ineffective [2].
Table 1. Baseline patient characteristics.
Variable LAAO (n = 139)
Age, years
[Mean ± SD] 61.75 ± 9.9
[Median (Q1±Q3)] 62 (56 ± 68.75)
[Range] 21–81
Female 46.0%
CHADS2 score
[Mean ± SD] 1.8 ± 1.0
[Median (Q1±Q3)] 2(1± 3)
CHA2DS2-VASc score
[Mean ± SD] 2.9 ± 1.6
[Median (Q1±Q3)] 3(2± 4)
HAS-BLED score
[Mean ± SD] 3.1 ± 1.1
[Median (Q1±Q3)] 3(2± 4)
Chronic Heart Failure 12.9%
Coronary Artery Disease 18.7%
Diabetes mellitus 20.1%
Previous TIA/stroke 26.6%
History of ablation 9.4%
Hypertension 93.5%
Chronic Obstructive Pulmonary Disease 6.5%
Pacemaker 17.3%
Pre-procedure medications
Vitamin K Antagonist 85.6%
Antiplatelet agents 12.2%
None 2.2%
LAA dimension
LAA width [mm] 28(22 ± 32)
LAA length [mm] 30(25 ± 37)
Number of lobe
1 lobe 44.7%
2 lobes 41.7%
3� lobes 13.6%
Indication for LAAC
Stroke/TIA while on OAC 28.8%
Failure/complication� while on OAC 10.8%
Contraindicated to OAC 12.9%
Labile INR 47.5%
�Failure of OAC: history of left atrial/left atrial appendage thrombus despite OAC; complication of OAC: history of
bleeding complication with OAC
https://doi.org/10.1371/journal.pone.0208710.t001
Long term outcomes after left atrial appendage closure—Stroke risk reduction over five years follow
PLOS ONE | https://doi.org/10.1371/journal.pone.0208710 December 19, 2018 4 / 9
The short-term safety and efficacy of the Lariat device has been demonstrated for diverse
patient groups [7–10,12]. However, long term data regarding epicardial LAAC devices is
limited.
In our patients the annual rate of stroke/TIA was 0.2% (one episode over 5 years). In similar
5-year follow-up studies the PREVAIL and PROTECT AF trials quoted a stroke rate of 1.7%
for the Watchman device [22] and the PLAATO study reported 3.8% [5]. Although these num-
bers seem to favor the epicardial approach, we note that the mean CHADS2-score and
CHA2DS2—VASc scores in this study were lower than in the endocardial study populations
[5,22].
In this study we have demonstrated an 81.3% reduction in the expected rate of thromboem-
bolic events. In the literature, there are only short-term observation study for stroke risk
reduction after LAAC with endocardial devices. 1-year follow-up data of the EWOLUTION
trail for Watchman device report 84% risk reduction for stroke prevention which is compara-
ble with our results which present over 5 years observation [23]. In our opinion, due to the
lack of randomized clinical trials in patients contraindicated for LAAO procedure, presented
method of calculated risk reduction to the expected rate based on CHA2DS2-VASc score in the
absence of stroke prevention therapy in this population seems to be a reasonable and compara-
ble solution for evaluating the effectiveness of LAAC therapy.
Table 2. Outcomes at follow-up.
Variable LAAO (n = 139)
LAA closure
Complete or < 1-mm leak 96.4%
< 2 mm leak 2.9%
< 3 mm leak 0.7%
< 1 year lost to follow-up 8.6% (n = 12)
Average follow-up
Days
[Mean ± SD] 1510 ± 362
[Median (Q1±Q3)] 1625 [1292 ±1757]
Months
[Mean ± SD] 50.3 ± 12.0
[Median (Q1±Q3)] 54(43± 59)
Death 5.5% (n = 7)
Cardiovascular 3.9% (n = 5)
Non-cardiovascular 0.8% (n = 1)
Reason unknown 0.8% (n = 1)
Thromboembolic events 2.4% (n = 3)
Ischemic stroke/TIA 0.8% (n = 1)
Thrombus in LA 1.6% (n = 2)
Severe bleeding 3.1% (n = 4)
Post procedure medications
Vitamin K Antagonist 44.1% (n = 56)
Vitamin K Antagonist + Aspirin 0.8% (n = 1)
New Oral Anticoagulants 14.4% (n = 20)
Aspirin 25.2% (n = 32)
LMWH 0.8% (n = 1)
None 13.4% (n = 17)
https://doi.org/10.1371/journal.pone.0208710.t002
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We also calculated a 78.4% reduction in bleeding risk compared to HAS-BLEED predic-
tions. In mentioned short-term results of EWOLUTION trail, the calculated bleeding risk
reduction was 54% for Watchman device and was lower compared to our results[23]. How-
ever, it is difficult to accurately interpret this result. In contrast to an endocardial devices as the
Watchman or the Amulet, epicardial exclusion with the Lariat uses a percutaneous approach
to achieve suture closure of the LAA and leaves no foreign body inside left atrium [9,24]. In
endocardial devices, the highest risk of thromboembolic events in the first 6 weeks post-proce-
dure therefore VKA is recommended for 45 days after procedure, dual dual antiplatelet ther-
apy for 6 months and aspirin thereafter [25,26]. After epicardial LAAC with Lariat permanent
closure of the LAA is observed [24] therefore anticoagulation regimen is life-long aspirin treat-
ment alone. Therefore our recommendation of aspirin monotherapy differs from the standard
protocols following endocardial procedures [25,26]
It should be also mentioned, besides thromboembolic and bleeding risk reduction, epicar-
dial LAAO present also hemodynamics and neurohormonal benefits [9,27]. In contrast to
endocardial devices, after LAAO using epicardial access with the Lariat, there were significant
increases in adiponectin and insulin, with decreased free fatty acids at 3 months post-proce-
dure [27]. Additionally, N-terminal pro-A-type natriuretic peptide and N-terminal pro-B-type
natriuretic peptide are significantly decreased in the acute phase after epicardial LAA device
implantation, which subsequently normalized at 3 months [9,27]. Post endocardial LAA device
implantation, the levels increased immediately and normalized after 24 h [27]. Additionally,
with Lariat device there is a possibility to perform post LAAC ablation procedure.
Early experience with the Lariat procedure in some centers was associated with higher com-
plication rates, related to epicardial access. It is important to notice that these findings were
with early experience of the 1st generation Lariat procedure. The majority of procedures were
performed with a large bore needle for pericardial access and no prophylactic use of colchicine.
However, modification of the initial technique in Europe and also in the U.S.[6,28] to deploy a
micropuncture needle and prophylactic colchicine has improved the safety profile of this
device dramatically. The device itself has also been modified. The second generation of Lariat
+ had larger snare accommodating LAA diameters up to 45 mm, steel braided shaft provides
increased columnar strength within the shaft allowing it to overcome any influence of the
epicardial sheath and distal marker of LARIAT for easy detection of correct orientation under
fluoroscopy.
Our initial experiences with Lariat + devices showed 100% successful rate of complete LAA
closure without any device or procedural related complications[29]. Comparable results of
Lariat+ were also reported from other center with less experience with epicardial devices[30].
Fig 1. Effectiveness in stroke risk and bleeding reduction (/ 100 patient-years) during follow-up.
https://doi.org/10.1371/journal.pone.0208710.g001
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Analysis of the FDA MAUDE databases between May 2009 and May 2016 [31] has shown
that LAAO was performed by the LARIAT approach in 4,889 cases. WATCHMAN was
implanted in 2,027 patients prior to FDA approval in March 2015 and 3,822 patients post-
approval. The composite outcome of stroke/TIA, pericardiocentesis, cardiac surgery, and
death occurred more frequently with WATCHMAN (cumulative incidence, 1.93% vs. 1.15%;
P = 0.001). Similar findings were observed for device embolization, cardiac surgery, and myo-
cardial infarction. Our findings of an overall mortality rate of 1.63% confirm this as a safe pro-
cedure over long-term follow-up. However, analysis of the FDA MAUDE databases present
some limitations. There was no comparison of patients profile, comorbidities, age, indications
for LAA procedure, the risk of stroke or bleeding which may impact of obtained results.
Conclusions
LAAC via an epicardial approach with the Lariat device is a safe and effective treatment in the
management of AF patients; 5-year follow-up data shows a reduction in the calculated risk of
stroke, thromboembolism and bleeding.
Study limitations
This is a non-randomized, prospective, observational single center study with its inherent limi-
tations. The major limitation for estimating the benefit of LAAC is the lack of a control group
and relying on calculated stroke or bleeding risks for analysis. Only the first generation of Lar-
iat devices were studied. Post-procedure anticoagulation was variable. This variability will
have had an impact on thromboembolic and bleeding risk, and therefore our calculations of
risk reduction.
Author Contributions
Conceptualization: Radoslaw Litwinowicz, Magdalena Bartus, Boguslaw Kapelak.
Data curation: Radoslaw Litwinowicz, Magdalena Bartus, Boguslaw Kapelak, Rafal Trabka.
Formal analysis: Radoslaw Litwinowicz, Magdalena Bartus, Maciej Brzeziński, Piotr Suwalski,
Boguslaw Kapelak, Dhanunjaya Lakkireddy, Randall J. Lee.
Funding acquisition: Krzysztof Bartus.
Investigation: Radoslaw Litwinowicz, Piotr Suwalski, Dhanunjaya Lakkireddy.
Methodology: Radoslaw Litwinowicz, Venkat Vuddanda.
Supervision: Marian Burysz.
Writing – original draft: Radoslaw Litwinowicz, Magdalena Bartus.
Writing – review & editing: Marian Burysz, Dhanunjaya Lakkireddy, Randall J. Lee, Krzysztof
Bartus.
References
1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, et al. (2012) 2012 focused update of the ESC
Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the man-
agement of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm
Association. Eur Heart J 33: 2719–2747. https://doi.org/10.1093/eurheartj/ehs253 PMID: 22922413
2. Grygier M, Wojakowski W, Smolka G, Demkow M, Wasek W, et al. (2018) [Left atrial appendage occlu-
sion: consensus document of Association of Cardiovascular Interventions and Heart Rhythm Section of
Polish Cardiac Society]. Kardiol Pol 76: 677–697. https://doi.org/10.5603/KP.a2018.0057 PMID:
29441512
Long term outcomes after left atrial appendage closure—Stroke risk reduction over five years follow
PLOS ONE | https://doi.org/10.1371/journal.pone.0208710 December 19, 2018 7 / 9
3. Pillarisetti J, Reddy YM, Gunda S, Swarup V, Lee R, et al. (2015) Endocardial (Watchman) vs epicardial
(Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type
of leaks and their clinical implications. Heart Rhythm 12: 1501–1507. https://doi.org/10.1016/j.hrthm.
2015.03.020 PMID: 25778430
4. Wiebe J, Franke J, Lehn K, Hofmann I, Vaskelyte L, et al. (2015) Percutaneous Left Atrial Appendage
Closure With the Watchman Device: Long-Term Results Up to 5 Years. JACC Cardiovasc Interv 8:
1915–1921. https://doi.org/10.1016/j.jcin.2015.07.040 PMID: 26738659
5. Block PC, Burstein S, Casale PN, Kramer PH, Teirstein P, et al. (2009) Percutaneous left atrial append-
age occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc
Interv 2: 594–600. https://doi.org/10.1016/j.jcin.2009.05.005 PMID: 19628179
6. Lakkireddy D, Afzal MR, Lee RJ, Nagaraj H, Tschopp D, et al. (2016) Short and long-term outcomes of
percutaneous left atrial appendage suture ligation: Results from a US multicenter evaluation. Heart
Rhythm 13: 1030–1036. https://doi.org/10.1016/j.hrthm.2016.01.022 PMID: 26872554
7. Bartus K, Bednarek J, Myc J, Kapelak B, Sadowski J, et al. (2011) Feasibility of closed-chest ligation of
the left atrial appendage in humans. Heart Rhythm 8: 188–193. https://doi.org/10.1016/j.hrthm.2010.
10.040 PMID: 21050893
8. Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, et al. (2013) Percutaneous left atrial appendage
suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am
Coll Cardiol 62: 108–118. https://doi.org/10.1016/j.jacc.2012.06.046 PMID: 23062528
9. Bartus K, Podolec J, Lee RJ, Kapelak B, Sadowski J, et al. (2017) Atrial natriuretic peptide and brain
natriuretic peptide changes after epicardial percutaneous left atrial appendage suture ligation using
LARIAT device. J Physiol Pharmacol 68: 117–123. PMID: 28456775
10. Litwinowicz R, Bartus M, Ceranowicz P, Kapelak B, Lakkireddy D, et al. (2018) Stroke risk reduction
after LAA occlusion in elderly patients with atrial fibrillation: long-term results. Pol Arch Intern Med.
11. Tzikas A, Holmes DR, Gafoor S, Ruiz CE, Blomström-Lundqvist C, et al. (2017) Percutaneous left atrial
appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection
requirements for clinical studies. Europace 19: 4–15. https://doi.org/10.1093/europace/euw141 PMID:
27540038
12. Litwinowicz R, Bartus M, Ceranowicz P, Kapelak B, Lakkireddy D, et al. (2018) Stroke risk reduction
after left atrial appendage occlusion in elderly patients with atrial fibrillation: longterm results. Pol Arch
Intern Med 128: 327–329. https://doi.org/10.20452/pamw.4264 PMID: 29768394
13. Freixa X, Gafoor S, Regueiro A, Cruz-Gonzalez I, Shakir S, et al. (2016) Comparison of Efficacy and
Safety of Left Atrial Appendage Occlusion in Patients Aged <75 to >/ = 75 Years. Am J Cardiol 117:
84–90. https://doi.org/10.1016/j.amjcard.2015.10.024 PMID: 26552507
14. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, et al. (2014) 2014 AHA/ACC/HRS guideline
for the management of patients with atrial fibrillation: executive summary: a report of the American Col-
lege of Cardiology/American Heart Association Task Force on practice guidelines and the Heart
Rhythm Society. Circulation 130: 2071–2104. https://doi.org/10.1161/CIR.0000000000000040 PMID:
24682348
15. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, et al. (2015) Assessment of
the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients
With Heart Failure With and Without Atrial Fibrillation. Jama 314: 1030–1038. https://doi.org/10.1001/
jama.2015.10725 PMID: 26318604
16. Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting
bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal
Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly) score. J Am Coll Cardiol 57: 173–180. https://doi.org/10.1016/j.jacc.2010.09.024
PMID: 21111555
17. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, et al. (2014) 2014 AHA/ACC/HRS guideline
for the management of patients with atrial fibrillation: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am
Coll Cardiol 64: e1–76. https://doi.org/10.1016/j.jacc.2014.03.022 PMID: 24685669
18. Litwinowicz R, Konstanty-Kalandyk J, Goralczyk T, Bartus K, Mazur P (2018) Dabigatran level monitor-
ing prior to idarucizumab administration in patients requiring emergent cardiac surgery. 45: 9–12.
https://doi.org/10.1007/s11239-017-1587-9 PMID: 29222699
19. Baman JR, Mansour M, Heist EK, Huang DT, Biton Y (2018) Percutaneous left atrial appendage occlu-
sion in the prevention of stroke in atrial fibrillation: a systematic review. Heart Fail Rev 23: 191–208.
https://doi.org/10.1007/s10741-018-9681-4 PMID: 29453694
Long term outcomes after left atrial appendage closure—Stroke risk reduction over five years follow
PLOS ONE | https://doi.org/10.1371/journal.pone.0208710 December 19, 2018 8 / 9
20. Bartuś K (2017) Left atrial appendage occlusion procedures. Kardiochir Torakochirurgia Pol 14: 1–4.
https://doi.org/10.5114/kitp.2017.66921 PMID: 28515740
21. Litwinowicz R, Witowski J, Sitkowski M, Filip G, Bochenek M, et al. (2018) Applications of low-cost 3D
printing in left atrial appendage closure using epicardial approaches–initial clinical experience. Kardio-
chirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery 15: 135–140.
22. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, et al. (2017) 5-Year Outcomes After Left Atrial
Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 70: 2964–2975.
https://doi.org/10.1016/j.jacc.2017.10.021 PMID: 29103847
23. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, et al. (2017) Efficacy and safety of left atrial
appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation:
1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 14: 1302–1308. https://doi.org/
10.1016/j.hrthm.2017.05.038 PMID: 28577840
24. Bartus K, Morelli RL, Szczepanski W, Kapelak B, Sadowski J, et al. (2014) Anatomic analysis of the left
atrial appendage after closure with the LARIAT device. Circ Arrhythm Electrophysiol 7: 764–767.
https://doi.org/10.1161/CIRCEP.113.001084 PMID: 25140024
25. Holmes DR Jr., Kar S, Price MJ, Whisenant B, Sievert H, et al. (2014) Prospective randomized evalua-
tion of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-
term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64: 1–12. https://doi.org/10.1016/j.jacc.
2014.04.029 PMID: 24998121
26. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, et al. (2009) Percutaneous closure of the left atrial
appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a rando-
mised non-inferiority trial. Lancet 374: 534–542. https://doi.org/10.1016/S0140-6736(09)61343-X
PMID: 19683639
27. Lakkireddy D, Turagam M, Afzal MR, Rajasingh J, Atkins D, et al. (2018) Left Atrial Appendage Closure
and Systemic Homeostasis: The LAA HOMEOSTASIS Study. J Am Coll Cardiol 71: 135–144. https://
doi.org/10.1016/j.jacc.2017.10.092 PMID: 29325636
28. Betts TR, Leo M, Panikker S, Kanagaratnam P, Koa-Wing M, et al. (2017) Percutaneous left atrial
appendage occlusion using different technologies in the United Kingdom: A multicenter registry. Cathe-
ter Cardiovasc Interv 89: 484–492. https://doi.org/10.1002/ccd.26782 PMID: 27651124
29. Bartus K, Gafoor S, Tschopp D, Foran JP, Tilz R, et al. (2016) Left atrial appendage ligation with the
next generation LARIAT(+) suture delivery device: Early clinical experience. Int J Cardiol 215: 244–
247. https://doi.org/10.1016/j.ijcard.2016.04.005 PMID: 27128539
30. Fink T, Schluter M, Tilz RR, Heeger CH, Lemes C, et al. (2018) Acute and long-term outcomes of
epicardial left atrial appendage ligation with the second-generation LARIAT device: a high-volume
electrophysiology center experience. Clin Res Cardiol.
31. Jazayeri MA, Vuddanda V, Turagam MK, Parikh V, Lavu M, et al. (2018) Safety profiles of percutaneous
left atrial appendage closure devices: An analysis of the Food and Drug Administration Manufacturer
and User Facility Device Experience (MAUDE) database from 2009 to 2016. 29: 5–13.
Long term outcomes after left atrial appendage closure—Stroke risk reduction over five years follow
PLOS ONE | https://doi.org/10.1371/journal.pone.0208710 December 19, 2018 9 / 9
